Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Fagron N.V. (FAGR.BR)
EUR23.95
-0.05 (-0.21%)
BE BRU Healthcare Drug Manufacturers - Specialty & Generic
Address
Venecoweg 20A 9810
Nazareth, BE
Nazareth, BE
CEO
Rafael Padilla
Website
fagron.com
IPO
2007-10-05
ISIN BE0003874915
Also trades on
Euronext Brussels · FAGR.BR (EUR)
Other OTC · ARSUF (USD)
Description
Fagron N.V. operates as a pharmaceutical compounding enterprise, dedicated to providing customized medicinal solutions for hospitals, pharmacies, clinics, and individual patients. The company is actively involved in developing innovative concepts, delivery systems, and formulations within the compounding sector. Its extensive offerings encompass essential raw materials, specialized equipment, semi-finished products, various drug vehicles, and both sterile and non-sterile custom-prepared medications. Additionally, through the Fagron Academy, the firm delivers educational and training programs to healthcare prescribers and pharmacists. With a significant global footprint, Fagron conducts operations across Latin America, North America, Europe, the Middle East, and Africa. Founded in 1990 and headquartered in Nazareth, Belgium, the company adopted its current name, Fagron NV, in January 2015, having previously been known as Arseus NV.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
EUR23.95
-0.05 (-0.21%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
109.1K
Beta
0.38
Float Shares
65.76M
Free Float %
89.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.82% | -4.37% | +0.42% | +5.93% | +13.15% | +13.15% | +11.32% | +41.35% | +29.57% | +234.26% | +161.67% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
23.95
DCF (Unlevered)
52.02
+117.2%
DCF (Levered)
45.27
+89.0%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 6 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
4.01
Safe zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
6 / 10
Developing
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
1 / 5
Low
P/E Score
2 / 5
Medium
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+9.2% ★ Q4'25: +21.6% (vs Q4'23)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+12.7% Q4'25: +21.6% (vs Q4'23)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+11.3% ★ Q4'25: +19.5% (vs Q4'23)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+15.4% ★ Q4'25: +15.6% (vs Q4'23)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+12.9% ★ Q4'25: +26.3% (vs Q4'23)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.6% Q4'25: +0.2% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×2.66× Q4'25: 1.31× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2007 actual |
Dec 2008 actual |
Dec 2009 actual |
Dec 2010 actual |
Dec 2011 actual |
Dec 2012 actual |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 5 EPS Ana. |
Dec 2027 5 Rev. Ana. 5 EPS Ana. |
Dec 2028 5 Rev. Ana. 5 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
304.37M
est: 308.91M (-1.5%)
|
354.51M
est: 359.88M (-1.5%)
|
391.32M
est: 396.61M (-1.3%)
|
424.06M
est: 430.32M (-1.5%)
|
492.33M
est: 497.69M (-1.1%)
|
547.02M
est: 550.56M (-0.6%)
|
386.12M
est: 595.55M (-35.2%)
|
447.06M
est: 454.13M (-1.6%)
|
473.00M
est: 476.97M (-0.8%)
|
421.84M
est: 419.83M (+0.5%)
|
436.93M
est: 435.57M (+0.3%)
|
471.68M
est: 472.11M (-0.1%)
|
534.70M
est: 540.12M (-1.0%)
|
555.97M
est: 557.75M (-0.3%)
|
573.81M
est: 571.54M (+0.4%)
|
683.88M
est: 676.88M (+1.0%)
|
762.99M
est: 820.76M (-7.0%)
|
871.96M
est: 862.77M (+1.1%)
|
952.17M
est: 942.73M (+1.0%)
|
1.11B
1.09B – 1.13B
+17.6% YoY
|
1.21B
1.17B – 1.25B
+8.7% YoY
|
1.33B
1.33B – 1.33B
+10.0% YoY
|
1.53B
1.50B – 1.58B
+15.6% YoY
|
| EBITDA |
37.27M
est: 58.82M (-36.6%)
|
39.81M
est: 22.25M (+78.9%)
|
43.08M
est: 12.45M (+245.9%)
|
49.17M
est: 20.20M (+143.4%)
|
59.64M
est: 29.96M (+99.1%)
|
65.64M
est: 34.07M (+92.6%)
|
72.00M
est: 34.46M (+109.0%)
|
110.17M
est: -32.84M (+435.5%)
|
42.33M
est: 22.54M (+87.8%)
|
49.52M
est: -197.42M (+125.1%)
|
92.39M
est: -37.63M (+345.5%)
|
87.17M
est: 41.54M (+109.8%)
|
108.04M
est: 45.34M (+138.3%)
|
115.50M
est: 44.48M (+159.7%)
|
116.00M
est: 47.70M (+143.2%)
|
135.62M
est: 51.37M (+164.0%)
|
134.12M
est: 155.39M (-13.7%)
|
146.56M
est: 163.39M (-10.3%)
|
192.64M
est: 178.49M (+7.9%)
|
209.97M
206.10M – 214.68M
+17.6% YoY
|
228.17M
221.95M – 237.25M
+8.7% YoY
|
251.02M
251.02M – 251.03M
+10.0% YoY
|
290.30M
283.61M – 299.43M
+15.6% YoY
|
| EBIT |
28.04M
est: 46.12M (-39.2%)
|
30.54M
est: 30.76M (-0.7%)
|
31.10M
est: 33.06M (-5.9%)
|
36.49M
est: 33.13M (+10.2%)
|
45.09M
est: 41.64M (+8.3%)
|
52.05M
est: 51.22M (+1.6%)
|
60.25M
est: 62.75M (-4.0%)
|
90.52M
est: 56.43M (+60.4%)
|
8.65M
est: 101.36M (-91.5%)
|
23.35M
est: 25.85M (-9.7%)
|
73.09M
est: 18.29M (+299.5%)
|
66.01M
est: 80.07M (-17.6%)
|
82.08M
est: 83.95M (-2.2%)
|
88.02M
est: 87.35M (+0.8%)
|
89.52M
est: 93.66M (-4.4%)
|
104.32M
est: 100.88M (+3.4%)
|
99.60M
est: 121.75M (-18.2%)
|
129.96M
est: 128.01M (+1.5%)
|
146.21M
est: 139.84M (+4.6%)
|
164.51M
161.48M – 168.20M
+17.6% YoY
|
178.77M
173.90M – 185.88M
+8.7% YoY
|
196.68M
196.67M – 196.68M
+10.0% YoY
|
227.44M
222.21M – 234.60M
+15.6% YoY
|
| Net Income |
16.26M
est: 47.40M (-65.7%)
|
14.90M
est: 18.99M (-21.5%)
|
19.64M
est: 16.42M (+19.6%)
|
22.48M
est: 21.29M (+5.6%)
|
28.14M
est: 25.91M (+8.6%)
|
43.91M
est: 31.08M (+41.2%)
|
-32.10M
est: 47.42M (-167.7%)
|
16.23M
est: -24.51M (+166.2%)
|
-202.33M
est: 17.43M (-1,260.5%)
|
-20.56M
est: -181.31M (+88.7%)
|
46.66M
est: -21.04M (+321.8%)
|
42.49M
est: 50.07M (-15.2%)
|
55.69M
est: 48.55M (+14.7%)
|
59.60M
est: 42.49M (+40.3%)
|
61.00M
est: 45.57M (+33.9%)
|
69.61M
est: 67.48M (+3.2%)
|
70.55M
est: 77.94M (-9.5%)
|
80.55M
est: 82.54M (-2.4%)
|
91.02M
est: 95.14M (-4.3%)
|
108.31M
96.02M – 123.14M
+13.8% YoY
|
119.36M
108.64M – 135.80M
+10.2% YoY
|
138.79M
127.18M – 155.69M
+16.3% YoY
|
179.38M
174.02M – 186.72M
+29.2% YoY
|
| SGA |
—
est: 72.31M (-100.0%)
|
—
est: 72.93M (-100.0%)
|
267.43M
est: 82.66M (+223.5%)
|
285.42M
est: 89.06M (+220.5%)
|
—
est: 106.17M (-100.0%)
|
—
est: 114.16M (-100.0%)
|
71.17M
est: 122.05M (-41.7%)
|
101.64M
est: 64.30M (+58.1%)
|
103.84M
est: 111.47M (-6.8%)
|
96.80M
est: 94.14M (+2.8%)
|
2.39M
est: 100.68M (-97.6%)
|
30.11M
est: 109.54M (-72.5%)
|
30.82M
est: 130.37M (-76.4%)
|
125.26M
est: 130.26M (-3.8%)
|
132.50M
est: 139.68M (-5.1%)
|
158.13M
est: 150.45M (+5.1%)
|
173.37M
est: 156.17M (+11.0%)
|
222.92M
est: 164.20M (+35.8%)
|
6.04M
est: 179.38M (-96.6%)
|
211.02M
207.13M – 215.75M
+17.6% YoY
|
229.30M
223.06M – 238.43M
+8.7% YoY
|
252.28M
252.27M – 252.28M
+10.0% YoY
|
291.74M
285.03M – 300.92M
+15.6% YoY
|
| EPS |
0.56
est: 0.65 (-13.8%)
|
0.44
est: 0.68 (-35.2%)
|
0.60
est: 0.79 (-23.7%)
|
0.69
est: 0.89 (-22.6%)
|
0.87
est: 1.04 (-16.6%)
|
1.33
est: 1.13 (+17.8%)
|
-0.97
est: 1.37 (-170.6%)
|
0.49
est: 1.73 (-71.7%)
|
-6.01
est: 1.22 (-594.1%)
|
-0.38
est: 0.47 (-180.3%)
|
0.65
est: 0.65 (-0.7%)
|
0.59
est: 0.73 (-19.0%)
|
0.78
est: 0.76 (+3.0%)
|
0.83
est: 0.86 (-3.8%)
|
0.84
est: 0.85 (-1.6%)
|
0.96
est: 0.91 (+5.5%)
|
0.97
est: 1.07 (-9.1%)
|
1.10
est: 1.12 (-1.6%)
|
1.25
est: 1.28 (-2.6%)
|
1.47
1.31 – 1.68
+14.8% YoY
|
1.65
1.48 – 1.85
+11.7% YoY
|
1.88
1.73 – 2.12
+14.5% YoY
|
2.44
2.37 – 2.54
+29.7% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-28 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-27 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-26 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-25 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-22 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-21 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-20 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-19 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-18 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-15 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-14 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-13 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-12 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-11 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-08 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-06 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-05 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-04 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-29 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-15 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
291.13M
OE per share TTM
3.99
Owner's Yield
16.50%
Maintenance CapEx ratio
38.14%
Maint CapEx / Avg PPE
20.6%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
38.2K
Shares Outstanding
73.35M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Rafael Padilla | Chief Executive Officer & Executive Director | 2M | male |
| Karin de Jong | Chief Financial Officer & Executive Director | 978.1K | female |
| Vera Bakker | Chief Operating Officer | 7.5K | female |
| Ignacio Artola | Global Head of Investor Relations | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for FAGR.BR
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
